FIRE-9 - PORT /​ AIO-KRK-0418

This is an open-label, randomized, controlled, multicenter, phase III study with two parallel arms. Patients with metastatic colorectal cancer after definite interventional therapy of all lesions are randomized in a 2:1 fashion (favoring active therapy) to investigate the efficacy, patient reported quality of life and safety of mFOLFOXIRI/mFOLFOX-6 as additive treatment (Arm A) versus active follow-up/surveillance (Arm B).

• Studientyp: randomisierte, multizentrische Studie
• Tumorart: Gastrointestinale Tumoren
• Entität: Darmkrebs
• Standorte:
  • Klinikum Stuttgart
  • E-Mail: scc-studienzentrale@klinikum-stuttgart.de
  • Tel.: 0711 278-30410
  • Website
  • Marienhospital
  • E-Mail: studienzentrum@vinzenz.de
  • Tel.: 0711 6489-8107
  • Website
• Rekrutierungsstatus: rekrutierend
• Alter: 18+
• Studienphase: Phase3
• Weitere Informationen